This ADC product is comprised of an anti-CD70 monoclonal antibody (clone h1F6) conjugated via a β-glucuronide linker to a doxorubicin . The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage.
ADC Target
- Alternative Names
- CD70; CD70 molecule; CD27L; CD27LG; TNFSF7; CD70 antigen; CD27-L; CD27 ligand; Ki-24 antigen; surface antigen CD70; tumor necrosis factor ligand superfamily member 7; tumor necrosis factor (ligand) superfamily, member 7;
- Target Entrez Gene ID
- 970
- Overview
- The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for TNFRSF27/CD27. It is a surface antigen on activated, but not on resting, T and B lymphocytes. It induces proliferation of costimulated T cells, enhances the generation of cytolytic T cells, and contributes to T cell activation. This cytokine is also reported to play a role in regulating B-cell activation, cytotoxic function of natural killer cells, and immunoglobulin sythesis.
ADC Antibody
- Overview
- Humanized Anti-CD70 lgG1 Antibody, clone # h1f6
ADC Linker
- Name
- β-glucuronide linker
- Description
- β-Glucuronide linkers belong to Enzymatically cleavable linkers, which have expected stability and provide facile release of the active drug. The cleavage of the β-glucuronide glycosidic bond relies on lysosomal enzyme β-glucuronidase, and this enzyme is abundantly present within lysosomes and is overexpressed in some tumor types, while the enzyme activity outside cells is low.
ADC payload drug
- Description
- Doxorubicin is the generic name for the trade name drug, Adriamycin®, as well as, Rubex®, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products